Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Notes underwriting agrmnt
Inv. presentation
Quarterly results
Appointed director
|
|
Fibrocell Science, Inc. (FCSC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/01/2019 |
GN
| Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – FCSC, PRTO, ARTX, ROAN |
| 09/23/2019 |
GN
| Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – UCFC, SEMG, ALDR, FCSC |
| 09/19/2019 |
GN
| SEMG, PVTL, FCSC and AVDR SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts |
| 09/16/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Fibrocell Science, Inc. to Castle Creek Pharmaceutical Holdings, Inc. is Fair to Shareholders |
| 09/12/2019 |
GN
| Castle Creek Pharmaceutical Holdings to Acquire Fibrocell |
| 08/14/2019 |
GN
| Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights |
| 05/30/2019 |
GN
| Fibrocell to Present at BIO International Convention 2019 |
| 05/29/2019 |
GN
| Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB |
| 05/15/2019 |
GN
| Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights |
| 05/09/2019 |
GN
| Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights |
| 04/15/2019 |
GN
| Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy |
| 03/27/2019 |
GN
| Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007 |
| 01/16/2019 |
GN
| Fibrocell to Present at Phacilitate Leaders World 2019 |
| 11/13/2018 |
GN
| Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights |
| 09/26/2018 |
GN
| Fibrocell to Present at Upcoming Industry and Investor Conferences |
| 09/25/2018 |
GN
| Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa |
| 09/05/2018 |
GN
| Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma |
| 08/29/2018 |
GN
| Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference |
| 07/05/2018 |
GN
| Fibrocell Announces Closing of $4.0 Million Registered Direct Offering |
| 07/02/2018 |
GN
| Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market |
| 05/29/2018 |
GN
| Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market |
| 05/24/2018 |
GN
| Fibrocell Announces One-for-Five Reverse Stock Split |
| 05/21/2018 |
GN
| Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa |
| 05/10/2018 |
GN
| Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights |
| 05/03/2018 |
GN
| Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights |
| 04/18/2018 |
GN
| Fibrocell Announces Review of Strategic Alternatives |
| 03/19/2018 |
GN
| Fibrocell Reports 2017 Financial Results and Recent Highlights |
| 03/06/2018 |
GN
| Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma |
| 02/05/2018 |
GN
| Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma |
| 01/24/2018 |
GN
| Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 |
| 12/11/2017 |
GN
| Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering |
| 12/07/2017 |
GN
| Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering |
| 11/13/2017 |
GN
| Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights |
| 10/02/2017 |
GN
| Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa |
|
|
|